Request Demo
Last update 20 Dec 2025
XmAb968
Last update 20 Dec 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD38 x CD3 bispecific antibody, AMG-424, CD38 X CD3 + [4] |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with XmAb968NCT05038644
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients With Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
NCT03445663
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma
100 Clinical Results associated with XmAb968
Login to view more data
100 Translational Medicine associated with XmAb968
Login to view more data
100 Patents (Medical) associated with XmAb968
Login to view more data
100 Deals associated with XmAb968
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Multiple Myeloma | Phase 1 | United States | 31 Jul 2018 | |
| Refractory Multiple Myeloma | Phase 1 | Australia | 31 Jul 2018 | |
| Relapse multiple myeloma | Phase 1 | United States | 31 Jul 2018 | |
| Relapse multiple myeloma | Phase 1 | Australia | 31 Jul 2018 | |
| Acute Lymphoblastic Leukemia | Phase 1 | United States | - | |
| Acute Myeloid Leukemia | Phase 1 | United States | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05038644 (ASH2023) Manual  | Phase 1 | Acute Myeloid Leukemia CD38 Expression | 12 | zmyjisirim(afmwwluiee) = jpcmppmgav kdclsxayrz (sqiraifnzr ) View more | Positive | 09 Dec 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free